Epigenetics:
Identical genetics, surprising differences;
Profound implications for medicine.

Epizyme is a biopharmaceutical company that is creating innovative drugs for major diseases based on important discoveries emerging from the field of Epigenetics. Epigenetics is a field of biology that explores mechanisms that alter chromosomes to control how a single individual's genome is differentially "read" to generate different cells, tissues and organs and how these mechanisms can go awry to cause serious diseases. Epizyme is initially focusing on a specific group of newly discovered epigenetic enzymes called histone methyltransferases (HMT), which play critical roles in normal biological functions and can be misregulated in cancer and other important diseases, including inflammatory, metabolic and neurologic disorders. Epizyme is developing an enabling and integrated platform that is generating a robust and sustainable drug pipeline of first-in-class inhibitors of HMTs targeted in cancer.

The Company has assembled a uniquely experienced Management Team along with a world-class Scientific Advisory Board and Board of Directors. Epizyme is headquartered in Cambridge, MA.